PPA
ALXN

Parametric Portfolio Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Parametric Portfolio Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-776,990
Closed -$143M – 3725
2021
Q2 		$143M Sell
776,990
-1,002
-0.1% -$172K 0.08% 233
2021
Q1 		$119M Buy
777,992
+35,830
+5% +$5.54M 0.07% 273
2020
Q4 		$116M Buy
742,162
+72,564
+11% +$9.32M 0.07% 245
2020
Q3 		$76.6M Buy
669,598
+97,636
+17% +$10.5M 0.06% 303
2020
Q2 		$64.2M Buy
571,962
+185,894
+48% +$19.7M 0.05% 338
2020
Q1 		$34.7M Buy
386,068
+70,790
+22% +$6.95M 0.03% 509
2019
Q4 		$34.1M Buy
315,278
+17,765
+6% +$1.9M 0.02% 655
2019
Q3 		$29.1M Sell
297,513
-56,498
-16% -$6.37M 0.02% 690
2019
Q2 		$46.4M Buy
354,011
+682
+0.2% +$87.9K 0.04% 456
2019
Q1 		$47.8M Buy
353,329
+56,024
+19% +$6.97M 0.04% 411
2018
Q4 		$28.9M Sell
297,305
-73,404
-20% -$8.68M 0.03% 583
2018
Q3 		$51.5M Sell
370,709
-20,784
-5% -$2.61M 0.05% 380
2018
Q2 		$48.6M Sell
391,493
-106,879
-21% -$12.5M 0.05% 379
2018
Q1 		$55.5M Buy
498,372
+8,594
+2% +$1.03M 0.05% 331
2017
Q4 		$58.6M Sell
489,778
-202,148
-29% -$24.6M 0.06% 314
2017
Q3 		$97.1M Buy
691,926
+37,663
+6% +$5.12M 0.11% 195
2017
Q2 		$79.6M Buy
654,263
+325,900
+99% +$37.9M 0.1% 208
2017
Q1 		$39.8M Sell
328,363
-408,761
-55% -$52.7M 0.06% 317
2016
Q4 		$90.2M Buy
737,124
+70,583
+11% +$8.64M 0.13% 159
2016
Q3 		$81.7M Buy
666,541
+348,874
+110% +$44.9M 0.12% 166
2016
Q2 		$37.1M Buy
317,667
+8,003
+3% +$1.14M 0.06% 335
2016
Q1 		$43.1M Sell
309,664
-78,323
-20% -$11.5M 0.07% 278
2015
Q4 		$74M Buy
387,987
+48,576
+14% +$8.49M 0.13% 160
2015
Q3 		$53.1M Sell
339,411
-19,439
-5% -$3.55M 0.1% 204
2015
Q2 		$64.9M Buy
358,850
+88,588
+33% +$15.3M 0.13% 158
2015
Q1 		$46.8M Buy
270,262
+26,363
+11% +$4.77M 0.09% 222
2014
Q4 		$45.1M Sell
243,899
-6,785
-3% -$1.26M 0.1% 218
2014
Q3 		$41.6M Sell
250,684
-3,162
-1% -$519K 0.09% 227
2014
Q2 		$39.7M Sell
253,846
-14,264
-5% -$2.25M 0.09% 239
2014
Q1 		$40.8M Buy
268,110
+37,596
+16% +$5.98M 0.1% 229
2013
Q4 		$30.6M Buy
230,514
+15,666
+7% +$1.88M 0.07% 283
2013
Q3 		$25M Buy
214,848
+14,212
+7% +$1.56M 0.07% 310
2013
Q2 		$18.5M Buy
+200,636
New +$19.3M 0.05% 381

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Parametric Portfolio Associates's ALXN Position: Q3 2021 in Review

Parametric Portfolio Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 776,990 shares — an estimated $143M sold.

Parametric Portfolio Associates first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $143M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Parametric Portfolio Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 776,990 Alexion Pharmaceuticals shares in Q3 2021, an estimated $143M.
  • Parametric Portfolio Associates first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Parametric Portfolio Associates's Alexion Pharmaceuticals position peaked at $143M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Parametric Portfolio Associates's 13F filing for Q3 2021, filed 15 Nov 2021.